FindTrial
Sign In

Study on the inhibition of intestinal endotoxemia by Xuebijing in the treatment of liver failure and hepatic encephalopathy

Study on the inhibition of intestinal endotoxemia by Xuebijing in the treatment of liver failure and hepatic encephalopathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125602
Enrollment
Unknown
Registered
2026-05-28
Start date
2024-01-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver failure and hepatic encephalopathy

Interventions

Experimental group:Xuebijing Injection 100ml qd intravenous infusion
Control group:Conventional treatment

Sponsors

Tianjin Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Meets the diagnostic criteria for slow and urgent (subacute) liver failure; Meets the diagnostic criteria for hepatic encephalopathy; Age range: 18-65 years old; There is no clear evidence of infection in other parts.

Exclusion criteria

Exclusion criteria: Merge and clarify the basis for infection in other parts, merge with major diseases such as tumors and immunodeficiency syndrome, and use antibiotics and live bacterial preparations in the past three months.

Design outcomes

Primary

MeasureTime frame
HE grade;Inflammatory factor;Blood NH3;—

Secondary

MeasureTime frame
liver function;—

Countries

China

Contacts

Public ContactLi Shengnan

Tianjin Second People's Hospital

lishengnan-002@163.com+86 136 2205 4947

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026